Calendar An icon of a desk calendar. Cancel An icon of a circle with a diagonal line across. Caret An icon of a block arrow pointing to the right. Email An icon of a paper envelope. Facebook An icon of the Facebook "f" mark. Google An icon of the Google "G" mark. Linked In An icon of the Linked In "in" mark. Logout An icon representing logout. Profile An icon that resembles human head and shoulders. Telephone An icon of a traditional telephone receiver. Tick An icon of a tick mark. Is Public An icon of a human eye and eyelashes. Is Not Public An icon of a human eye and eyelashes with a diagonal line through it. Pause Icon A two-lined pause icon for stopping interactions. Quote Mark A opening quote mark. Quote Mark A closing quote mark. Arrow An icon of an arrow. Folder An icon of a paper folder. Breaking An icon of an exclamation mark on a circular background. Camera An icon of a digital camera. Caret An icon of a caret arrow. Clock An icon of a clock face. Close An icon of the an X shape. Close Icon An icon used to represent where to interact to collapse or dismiss a component Comment An icon of a speech bubble. Comments An icon of a speech bubble, denoting user comments. Comments An icon of a speech bubble, denoting user comments. Ellipsis An icon of 3 horizontal dots. Envelope An icon of a paper envelope. Facebook An icon of a facebook f logo. Camera An icon of a digital camera. Home An icon of a house. Instagram An icon of the Instagram logo. LinkedIn An icon of the LinkedIn logo. Magnifying Glass An icon of a magnifying glass. Search Icon A magnifying glass icon that is used to represent the function of searching. Menu An icon of 3 horizontal lines. Hamburger Menu Icon An icon used to represent a collapsed menu. Next An icon of an arrow pointing to the right. Notice An explanation mark centred inside a circle. Previous An icon of an arrow pointing to the left. Rating An icon of a star. Tag An icon of a tag. Twitter An icon of the Twitter logo. Video Camera An icon of a video camera shape. Speech Bubble Icon A icon displaying a speech bubble WhatsApp An icon of the WhatsApp logo. Information An icon of an information logo. Plus A mathematical 'plus' symbol. Duration An icon indicating Time. Success Tick An icon of a green tick. Success Tick Timeout An icon of a greyed out success tick. Loading Spinner An icon of a loading spinner. Facebook Messenger An icon of the facebook messenger app logo. Facebook An icon of a facebook f logo. Facebook Messenger An icon of the Twitter app logo. LinkedIn An icon of the LinkedIn logo. WhatsApp Messenger An icon of the Whatsapp messenger app logo. Email An icon of an mail envelope. Copy link A decentered black square over a white square.

New prostate cancer test ‘could help save lives and prolong life expectancy’

A simple blood test has been developed that detects aggressive and potentially lethal prostate cancer by identifying rare free-ranging tumour cells (iStock)
A simple blood test has been developed that detects aggressive and potentially lethal prostate cancer by identifying rare free-ranging tumour cells (iStock)

A simple blood test has been developed that detects aggressive and potentially lethal prostate cancer by identifying rare free-ranging tumour cells.

The cells can flag up patients who have a 10-fold increased risk of dying from their disease, allowing targeted treatments to be delivered as quickly as possible.

Each year more than 40,000 men in the UK are diagnosed with prostate cancer. Often the disease is localised, slow growing, and relatively easy to treat.

In other cases, the cancer is much more aggressive and likely to spread or “metastasise” to other parts of the body, such as the bones and liver.

Spotting these dangerous cancers early on before they produce secondary tumours that show up on scans is not easy.

The new test, described in the journal Clinical Cancer Research, is said to provide a highly accurate and straightforward way to single out patients with life-threatening prostate cancer.

It identifies two specific types of circulating tumour cell (CTC) linked to metastasis and poor patient survival. These are tumour fragments that have broken away from the primary cancer and are travelling freely through the blood stream.

In addition the test picks up megakaryocytes, large bone marrow cells that generate platelets and appear to aid prostate cancer survival.

Lead scientist Dr Yong-Jie Lu, from Queen Mary, University of London, said: “This work opens up a wide range of exciting opportunities to benefit cancer patients.

“We have already started to test more patient samples and will soon move on to wider clinical trials to confirm the efficacy of the test.

“We are also working to see if this test can be used on other types of cancer.”

Researchers analysed blood samples from 81 prostate cancer patients using a new cell-capture technology called Parsortix, developed by the British company Angle plc.

The team found that combining the results for one of the CTCs with the standard prostate cancer blood marker PSA – Prostate Specific Antigen – predicted metastasis with 92% accuracy. Used on its own, PSA testing is known to be highly unreliable.

A scoring system based on the test which took account of both CTC types and megakaryocytes was able to identify patients who were 10 times more likely than others to die prematurely.

Rebecca Porta, from the charity Orchid – Fighting Male Cancer, which funded the study, said: “This is a very promising study for patients and has the potential to significantly increase the ability of clinicians to act earlier to treat those who are at a higher risk of dying earlier from their cancer.

“Delivering more appropriate treatment more quickly could help to save lives and prolong life expectancy.”

Dr Catherine Pickworth, science information officer at Cancer Research UK, said: “Cancers spreading to new areas of the body is the main reason why people die from the disease.

“This study shows a potential new way of helping to monitor this spread in men with prostate cancer.”

The two types of circulating tumour cell are known as EMTing and EMTed CTCs. They are at different stages of a transformation process that allows them to acquire stem cell-like properties. Both have previously been notoriously difficult to capture and measure.